Research programme: pain therapies - ACADIA/Allergan

Drug Profile

Research programme: pain therapies - ACADIA/Allergan

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 08 Oct 2015 Research programme: pain therapies - ACADIA/Allergan is available for licensing as of 26 Feb 2015.
  • 04 Apr 2012 Alpha-adrenergic agonists are still in preclinical development for Pain in USA
  • 01 Mar 2006 ACADIA and Allergan have extended the term of their neuropathic pain therapies research programme for 2 years until March 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top